Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
37 studies found for:    "Porphyria"
Show Display Options
RSS Create an RSS feed from your search for:
"Porphyria"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria
Condition: Acute Porphyrias
Interventions: Biological: Panhematin;   Other: Placebo
2 Completed Observational Study of Acute Intermittent Porphyria Patients
Condition: Acute Intermittent Porphyria
Intervention:
3 Recruiting A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP)
Condition: Acute Intermittent Porphyria
Interventions: Drug: ALN-AS1;   Drug: Sterile Normal Saline (0.9% NaCl)
4 Recruiting Longitudinal Study of the Porphyrias
Conditions: Acute Porphyrias;   Cutaneous Porphyrias
Intervention:
5 Recruiting Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine;   Procedure: Phlebotomy
6 Completed Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
Condition: Acute Intermittent Porphyria
Interventions: Genetic: rAAV2/5-PBGD vector dosage 1;   Genetic: rAAV2/5-PBGD vector dosage 2;   Genetic: rAAV2/5-PBGD vector dosage 3;   Genetic: rAAV2/5-PBGD vector dosage 4
7 Enrolling by invitation A Study to Evaluate Long-term Safety and Clinical Activity of ALN-AS1 in Patient With Acute Intermittent Porphyria (AIP)
Condition: Acute Intermittent Porphyria
Intervention: Drug: ALN-AS1
8 Completed Risk Factors of Porphyria Cutanea Tarda (PCT)
Condition: Porphyria Cutanea Tarda
Intervention:
9 Completed
Has Results
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Intervention: Drug: Deferasirox
10 Not yet recruiting Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Condition: Acute Intermittent Porphyria
Intervention:
11 Unknown  Studies in Porphyria I: Characterization of Enzyme Defects
Condition: Porphyria
Intervention:
12 Completed Study of Nutritional Factors in Porphyria
Condition: Porphyria
Intervention:
13 Completed Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias
Condition: Porphyria
Interventions: Drug: heme arginate;   Drug: tin mesoporphyrin
14 Completed Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks
Condition: Porphyria
Intervention: Drug: luteinizing hormone-releasing factor
15 Completed Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria
Condition: Porphyria
Interventions: Drug: heme arginate;   Drug: tin mesoporphyrin
16 Completed Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria
Condition: Porphyria
Interventions: Drug: heme arginate;   Drug: tin mesoporphyrin
17 Completed Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
Condition: Porphyria
Interventions: Drug: heme arginate;   Drug: tin mesoporphyrin
18 Active, not recruiting EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Condition: Acute Hepatic Porphyria
Intervention:
19 Enrolling by invitation Acute Porphyria Biomarkers
Conditions: Acute Intermittent Porphyria;   Hereditary Coproporphyria;   Variegate Porphyria
Intervention: Drug: Hemin
20 Unknown  Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Intervention: Drug: Exjade

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.